SVC-Survivin™
Cancer (specifics not detailed)
Pre-clinicalActive
Key Facts
About SiVEC Biotechnologies
SiVEC Biotechnologies is a private, preclinical-stage biotech company pioneering a bacterial-based drug delivery platform. Its core technology, BactPac™, uses engineered bacteria to produce and deliver therapeutic payloads directly to target tissues, aiming to overcome limitations of viral vectors and lipid nanoparticles. The company is advancing an internal pipeline led by SVC-KRAb™, a pan-RAS cancer therapeutic, while also seeking partnerships with pharmaceutical companies to deploy its platform for next-generation nucleic acid and gene therapies. SiVEC represents a novel approach in the targeted delivery space, with potential applications across multiple high-need therapeutic areas.
View full company profile